

Psychopharmacologic Drugs Advisory Committee Meeting

April 7, 2009

Hilton Washington DC/Silver Spring
Silver Spring, Maryland

Meeting Roster

PSYCHOPHARMACOLOGIC DRUGS ADVISORY COMMITTEE

MEMBERS (Voting)

Gail W. Griffith

(Consumer Representative)

Writer and Activist
Washington, DC

Marcia J. Slattery, M.D.

Associate Professor of Psychiatry
University of Wisconsin
School of Medicine and Public Health
Department of Psychiatry
Madison, WI

PSYCHOPHARMACOLOGIC DRUGS ADVISORY COMMITTEE

TEMPORARY MEMBERS (Voting)

Barbara Geller, M.D.

Professor, Department of Psychiatry
Washington University in St. Louis
St. Louis, MO

Richard P. Malone, M.D.

Professor of Psychiatry
Drexel University College of Medicine
Philadelphia, PA

Wayne K. Goodman, M.D. (Acting Chair)

Division of Adult Translational Research and
and Treatment Development
National Institute of Mental Health
National Institute of Health
Bethesda, MD

Daniel S. Pine, M.D.

Chief of Child Adolescent Research
National Institute of Health
National Institute of Mental Health
Mood and Anxiety Disorders Program
Bethesda, MD

Robert L. Hendren, D.O.

Professor of Psychiatry
Tsakopoulos-Vismara Chair &
Exec. Director, M.I.N.D. Institute
Chief, Child and Adolescent Psychiatry
President, American Academy of Child
and Adolescent Psychiatry
University of California at Davis
Sacramento, CA

Andrew Winokur, M.D., Ph.D.

Professor, Departments of Psychiatry
and Pharmacology
University of Connecticut School of Medicine
Farmington, CT

Margy Lawrence

(Patient Representative)
Potomac, MD

Psychopharmacologic Drugs Advisory Committee Meeting

April 7, 2009

Hilton Washington DC/Silver Spring
Silver Spring, Maryland

Meeting Roster

**PSYCHOPHARMACOLOGIC DRUGS ADVISORY COMMITTEE MEMBERS
INDUSTRY REPRESENTATIVE (Non-Voting)**

William Z. Potter, M.D., Ph.D.

Vice President, Translational Neuroscience
Merck & Co., Inc
North Wales, PA

**CARDIOVASCULAR AND RENAL DRUGS ADVISORY COMMITTEE
MEMBERS (Voting)**

Robert Harrington, M.D., F.A.C.C.

Professor of Medicine
Division of Cardiology
Department of Medicine
Duke University Medical School
Durham, NC

**CARDIOVASCULAR AND RENAL DRUGS ADVISORY COMMITTEE
TEMPORARY MEMBERS (Voting)**

Christopher B. Granger, M.D., F.A.C.C.

Professor of Medicine
Director, Cardiac Care Unit
Duke University Medical Center
Durham, NC

Sheryl Kelsey, Ph.D.

Professor of Epidemiology
University of Pittsburgh
Pittsburgh, PA

**DRUG SAFETY AND RISK MANAGEMENT ADVISORY COMMITTEE
TEMPORARY MEMBERS (Voting)**

Warren B. Bilker, Ph.D.

Associate Professor
The University of Pennsylvania School of Medicine
Department of Biostatistics and Epidemiology
Philadelphia, PA

Ruth S. Day, Ph.D.

Director, Medical Cognition Laboratory
Duke University
Durham, NC

Psychopharmacologic Drugs Advisory Committee Meeting
April 7, 2009
Hilton Washington DC/Silver Spring
Silver Spring, Maryland

Meeting Roster

FDA PARTICIPANTS (Non-Voting)

Robert Temple, M.D.

Director, Office of Drug Evaluation I (ODE-1)
Office of New Drugs (OND)
Center for Drug Evaluation and Research (CDER),
FDA

CDR Mitchell V. Mathis, M.D.

Deputy Director, DPP
OND, CDER, FDA

Thomas P. Laughren, M.D.

Director, Division of Psychiatry Products (DPP)
OND, CDER, FDA

Marc B. Stone, M.D.

Senior Medical Reviewer, DPP
OND, CDER, FDA

DRAFT